Evidence map›Paper›PMID 33753854›Full record

ArticleScientific reports2021

Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer.

Katsutaka Mitachi, Kyohei Ariake, Hiroki Shima, Satoko Sato, Takayuki Miura, Shimpei Maeda, Masaharu Ishida, Masamichi Mizuma, Hideo Ohtsuka, Takashi Kamei and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Katsutaka MitachiDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kyohei AriakeDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan. ariake@surg.med.tohoku.ac.jp.
Hiroki ShimaDepartment of Biochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan.
Satoko SatoDepartment of Pathology, Tohoku University Hospital, Sendai, Japan.
Takayuki MiuraDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Shimpei MaedaDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Masaharu IshidaDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Masamichi MizumaDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hideo OhtsukaDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Takashi KameiDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kazuhiko IgarashiDepartment of Biochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan.
Michiaki UnnoDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tohoku University · JPTohoku University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The collagen gel droplet-embedded drug sensitivity test (CD-DST) was revealed to be useful for predicting the effect of S-1 adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDAC). However, collection of an adequate number of PDAC cells is difficult due to the surrounding fibroblasts. Thus, the aim of this study was to discover novel biomarkers to predict chemosensitivity based on the CD-DST results. Proteomics analysis was performed using liquid chromatography tandem mass spectrometry (LC-MS/MS). Candidate proteins were validated in patients with 5-FU CD-DST results via immunohistochemistry (IHC). The relationships between the candidate proteins and the effect of the adjuvant S-1 were investigated via IHC. Among the 2696 proteins extracted by LC-MS/MS, C1TC and SAHH could accurately predict the CD-DST results. Recurrence-free survival (RFS) was significantly improved in the IHC-positive group compared with the IHC-negative group in both factors. The negative group did not show a significant difference from the group that did not receive S-1. The double-positive group was associated with significantly prolonged RFS compared to the no adjuvant chemotherapy group. C1TC and SAHH have been shown to be useful biomarkers for predicting 5-FU sensitivity as a substitute for the CD-DST in adjuvant chemotherapy for PDAC.

Indexed as

AdenocarcinomaAdenosylhomocysteinaseAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, PharmacologicalBiomarkers, TumorCarcinoma, Pancreatic DuctalChromatography, LiquidCollagenDisease-Free SurvivalDrug Resistance, NeoplasmDrug Screening Assays, AntitumorFemaleFluorouracilHumansAdenosylhomocysteinaseAHCY protein, humanBiomarkers, PharmacologicalBiomarkers, TumorCollagenFluorouracilNeoplasm ProteinsTensinsTNS2 protein, human

Identifiers

PMID33753854
PMCPMC7985196
OpenAlexW3136247127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.